Department of Cellular, Computational and Integrative Biology (CIBIO) and.
Dulbecco Telethon Institute, University of Trento, Povo, Italy.
J Clin Invest. 2020 Nov 2;130(11):5652-5664. doi: 10.1172/JCI142031.
Muscular dystrophies are a heterogeneous group of genetic diseases, characterized by progressive degeneration of skeletal and cardiac muscle. Despite the intense investigation of different therapeutic options, a definitive treatment has not been developed for this debilitating class of pathologies. Cell-based therapies in muscular dystrophies have been pursued experimentally for the last three decades. Several cell types with different characteristics and tissues of origin, including myogenic stem and progenitor cells, stromal cells, and pluripotent stem cells, have been investigated over the years and have recently entered in the clinical arena with mixed results. In this Review, we do a roundup of the past attempts and describe the updated status of cell-based therapies aimed at counteracting the skeletal and cardiac myopathy present in dystrophic patients. We present current challenges, summarize recent progress, and make recommendations for future research and clinical trials.
肌肉萎缩症是一组异质性的遗传疾病,其特征是骨骼肌和心肌进行性退化。尽管对不同的治疗选择进行了深入研究,但对于这种衰弱性病理类别仍未开发出明确的治疗方法。在过去的三十年中,肌肉萎缩症的细胞疗法一直在进行实验研究。多年来,已经研究了多种具有不同特性和起源组织的细胞类型,包括肌源性干细胞和祖细胞、基质细胞和多能干细胞,并已将其应用于临床,取得了不同的结果。在这篇综述中,我们总结了过去的尝试,并描述了旨在对抗肌肉萎缩症患者骨骼和心肌病变的基于细胞的治疗方法的最新进展。我们提出了当前的挑战,总结了最近的进展,并为未来的研究和临床试验提出了建议。